Clinical significance of antibodies against calcitonin
The DOI matches its Crossref record.
Abstract
Calcitonin (CT) inhibits osteoclast-mediated bone resorption and is being used to treat Paget's disease of bone, hypercalcemia of malignancy and postmenopausal osteoporosis. The formation of antibodies against heterologuous calcitonins like salmon calcitonin (sCT) is common and occurs in 40-70% of the patients treated for more than 4 months. Not all of these patients, however, develop a secondary resistance to sCT, therefore the clinical significance of sCT antibodies is discussed controversially. In vivo and in vitro approaches demonstrate a neutralizing effect in 35 to 60% of the patient sera with antibodies against sCT. These neutralizing antibodies appear to explain most cases of clinically relevant secondary resistance to sCT treatment, which occurs in 25-45% of the patients after treatment periods of 6 months and longer. A positive treatment response to human CT after development of secondary resistance to sCT proves the diagnosis of antibody related resistance. Few cases develop secondary resistance in the absence of sCT binding antibodies, the mechanism of this phenomenon is unclear. Antibody related resistance is a significant problem in long term treatment with sCT. Especially in conditions like postmenopausal osteoporosis, where no readily accessable marker of treatment response is available, the development of sCT antibodies and their possible neutralizing effect has to be considered.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“sCT has been shown to be safe, and although a large proportion of patients treated with sCT develop antibodies against it, it is generally believed that these have minimal clinical impact (85).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [85]
Citations
Cites
Still being checked.
Cited by
Immunogenicity of therapeutic proteins: Clinical implications and future prospects
Schellekens, H. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80075-3 · Cited by 556
The Activity of Peptides of the Calcitonin Family in Bone
Naot, D., Musson, D. S., & Cornish, J. (2019) · Physiological Reviews · doi:10.1152/physrev.00066.2017 · Cited by 141
Metadata
- Authors
- Grauer, A., Ziegler, R., & Raue, F.
- Affiliations
- Heidelberg University (DE)
- ORCID
- Venue
- Experimental and Clinical Endocrinology & Diabetes
- Publisher
- Georg Thieme Verlag KG
- Published
- 2009-07-15
- Volume
- 103
- Issue
- 06
- Pages
- 345-351
- ISSN
- 0947-7349 (ISSN-L)
- 1439-3646
- OpenAlex
- W1976679680
- Cited by
- 38
- References
- 0
- Citations by year
- 2025: 1 · 2024: 3 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 2 · 2016: 1 · 2013: 2 · 2012: 2
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Experimental and Clinical Endocrinology & Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Keywords
- calcitonin, salmon calcitonin, neutralizing antibodies, postmenopausal osteoporosis, hypercalcemia of malignancy, Paget's disease of bone, human calcitonin, osteoclast resorption
- MeSH terms
- Animals, Antibodies, Calcitonin, Drug Resistance, Female, Humans, Hypercalcemia, Neoplasms, Osteitis Deformans, Osteoporosis, Postmenopausal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical significance of antibodies against calcitonin. https://app.cochat.ai/papers/10.1055/s-0029-1211376
- The paper
- Grauer, A., Ziegler, R., & Raue, F. (2009). Clinical significance of antibodies against calcitonin. Experimental and Clinical Endocrinology & Diabetes. https://doi.org/10.1055/s-0029-1211376
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.